Swedish Orphan Biovitrum
135 articles with Swedish Orphan Biovitrum
Sobi™ Completes Acquisition of Synagis® US Rights From AstraZeneca and Exercises Authorisation to Issue Shares
Swedish Orphan Biovitrum AB announced today that it has completed the acquisition from AstraZeneca of rights to Synagis® (palivizumab) in the US as well as rights to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US, as announced on 13 November 2018.
Data Presented at ASH Support Emapalumab as an Innovative, Targeted Therapeutic Option for Primary HLH
Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are presenting data from the pivotal phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) as part of the late-breaking abstract session at the 60th Annual Meeting of the American Society of Hematology (ASH), taking place 1-4 December 2018, in San Diego.
Late-breaking Abstract at ASH Supports Evidence on Transformative First-ever Treatment in Primary HLH
Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are pleased to announce that the abstract "Safety and efficacy of emapalumab in paediatric patients with primary hemophagocytic lymphohistiocytosis" was accepted as a late-breaking abstract at the 60th Annual Meeting of the American Society of Hematology in San Diego, California, 1-4 December 2018, for oral presentation.
FDA Approves Gamifant® (emapalumab), the First and Only Treatment for Primary Haemophagocytic Lymphohistiocytosis (HLH)
Swedish Orphan Biovitrum AB today announce that the US Food and Drug Administration (FDA) has approved Gamifant® (emapalumab-lzsg), an interferon gamma (IFNγ) blocking antibody for the treatment of paediatric (new born and older) and adult patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.
Swedish Orphan Biovitrum AB has appointed Paula Treutiger as Head of Communications and Investor Relations. Paula will join Sobi on 1 January 2019 and be part of Sobi's Executive Committee.
Swedish Orphan Biovitrum AB has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US.
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the third quarter 2018. Total revenues grew 45 per cent compared with Q3 2017 (34 per cent at constant exchange rates (CER)) and amounted to SEK 2,315 M. EBITA was SEK 933 M, an increase of 74 per cent for the quarter, and gross margin amounted to 75 per cent.
On 31 October, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2018.
Following approvals from relevant competition authorities, Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) has completed the acquisition of the perpetual global rights to emapalumab from Novimmune SA.
Swedish Orphan Biovitrum AB (publ) (Sobi™) has appointed Anne Marie de Jonge Schuermans as Head of Sobi's new Technical Operations organisation, bringing together Sobi's Manufacturing Operations/Biological Development & Supply, Quality, Supply Chain, Procurement and Environment & Safety operations.
First Patient Dosed in Phase 1/2 Study Evaluating SOBI003 for Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the first patient has been dosed in the phase 1/2 study SOBI003-001.
The event will be hosted by Sobi's CEO and President, Guido Oelkers, and the presentation will be held in English.
Sobi™ Discloses Payments to Healthcare Professionals and Healthcare Organisations to Increase Transparency
Swedish Orphan Biovitrum AB announces that the company has made all payments and transfers of value to healthcare professionals and organisations from 2017 publicly available.
On 26 April, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the first quarter 2018.
Bioverativ Release: New Data Show Extended Prophylactic Dosing With ALPROLIX Provides Safe and Effective Protection in People With Severe Hemophilia B
The analysis is being presented in a poster session at the 59th Annual Meeting of the American Society of Hematology (ASH).
Sobi Receives Approval From Health Canada for Orfadin (nitisinone) Oral Suspension for the Treatment of HT-1
Orfadin is the first medicine approved in multiple countries globally for use in combination with dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 (HT-1).
Bioverativ Release: Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for Hemophilia A Patients Following Prophylactic Treatment With ELOCTATE
Interim data show participants enrolled in the ASPIRE extension study demonstrated continuous improvement in joint health over a nearly three-year period with prophylactic dosing of ELOCTATE.
Sobi Receives Approval From The FDA For Once-Daily Dosing Frequency Of Orfadin (Nitisinone) For The Treatment Of HT-1